INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28701, 3025, 'Topiramate', 'Kidney Diseases', 'The major route of elimination of carbonic anhydrase inhibitors is through the kidney.  These drugs should be administered cautiously in patients with reduced renal function and a dose adjustment might be required depending on the level of impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28702, 3026, 'Topiramate', 'Kidney Diseases', 'The major route of elimination of carbonic anhydrase inhibitors is through the kidney.  These drugs should be administered cautiously in patients with reduced renal function and a dose adjustment might be required depending on the level of impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28703, 8555, 'Topiramate', 'Kidney Diseases', 'The major route of elimination of carbonic anhydrase inhibitors is through the kidney.  These drugs should be administered cautiously in patients with reduced renal function and a dose adjustment might be required depending on the level of impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28704, 11537, 'Topiramate', 'Kidney Diseases', 'The major route of elimination of carbonic anhydrase inhibitors is through the kidney.  These drugs should be administered cautiously in patients with reduced renal function and a dose adjustment might be required depending on the level of impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28705, 16780, 'Topiramate', 'Kidney Diseases', 'The major route of elimination of carbonic anhydrase inhibitors is through the kidney.  These drugs should be administered cautiously in patients with reduced renal function and a dose adjustment might be required depending on the level of impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28706, 17218, 'Topiramate', 'Kidney Diseases', 'The major route of elimination of carbonic anhydrase inhibitors is through the kidney.  These drugs should be administered cautiously in patients with reduced renal function and a dose adjustment might be required depending on the level of impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28707, 18427, 'Topiramate', 'Kidney Diseases', 'The major route of elimination of carbonic anhydrase inhibitors is through the kidney.  These drugs should be administered cautiously in patients with reduced renal function and a dose adjustment might be required depending on the level of impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28708, 18428, 'Topiramate', 'Kidney Diseases', 'The major route of elimination of carbonic anhydrase inhibitors is through the kidney.  These drugs should be administered cautiously in patients with reduced renal function and a dose adjustment might be required depending on the level of impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28709, 18429, 'Topiramate', 'Kidney Diseases', 'The major route of elimination of carbonic anhydrase inhibitors is through the kidney.  These drugs should be administered cautiously in patients with reduced renal function and a dose adjustment might be required depending on the level of impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28710, 27427, 'Topiramate', 'Kidney Diseases', 'The major route of elimination of carbonic anhydrase inhibitors is through the kidney.  These drugs should be administered cautiously in patients with reduced renal function and a dose adjustment might be required depending on the level of impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28711, 27428, 'Topiramate', 'Kidney Diseases', 'The major route of elimination of carbonic anhydrase inhibitors is through the kidney.  These drugs should be administered cautiously in patients with reduced renal function and a dose adjustment might be required depending on the level of impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28712, 27429, 'Topiramate', 'Kidney Diseases', 'The major route of elimination of carbonic anhydrase inhibitors is through the kidney.  These drugs should be administered cautiously in patients with reduced renal function and a dose adjustment might be required depending on the level of impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28713, 28295, 'Topiramate', 'Kidney Diseases', 'The major route of elimination of carbonic anhydrase inhibitors is through the kidney.  These drugs should be administered cautiously in patients with reduced renal function and a dose adjustment might be required depending on the level of impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28714, 28296, 'Topiramate', 'Kidney Diseases', 'The major route of elimination of carbonic anhydrase inhibitors is through the kidney.  These drugs should be administered cautiously in patients with reduced renal function and a dose adjustment might be required depending on the level of impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28715, 28297, 'Topiramate', 'Kidney Diseases', 'The major route of elimination of carbonic anhydrase inhibitors is through the kidney.  These drugs should be administered cautiously in patients with reduced renal function and a dose adjustment might be required depending on the level of impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28716, 28298, 'Topiramate', 'Kidney Diseases', 'The major route of elimination of carbonic anhydrase inhibitors is through the kidney.  These drugs should be administered cautiously in patients with reduced renal function and a dose adjustment might be required depending on the level of impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28717, 28329, 'Topiramate', 'Kidney Diseases', 'The major route of elimination of carbonic anhydrase inhibitors is through the kidney.  These drugs should be administered cautiously in patients with reduced renal function and a dose adjustment might be required depending on the level of impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28718, 28330, 'Topiramate', 'Kidney Diseases', 'The major route of elimination of carbonic anhydrase inhibitors is through the kidney.  These drugs should be administered cautiously in patients with reduced renal function and a dose adjustment might be required depending on the level of impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28719, 28333, 'Topiramate', 'Kidney Diseases', 'The major route of elimination of carbonic anhydrase inhibitors is through the kidney.  These drugs should be administered cautiously in patients with reduced renal function and a dose adjustment might be required depending on the level of impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28720, 28334, 'Topiramate', 'Kidney Diseases', 'The major route of elimination of carbonic anhydrase inhibitors is through the kidney.  These drugs should be administered cautiously in patients with reduced renal function and a dose adjustment might be required depending on the level of impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28721, 28339, 'Topiramate', 'Kidney Diseases', 'The major route of elimination of carbonic anhydrase inhibitors is through the kidney.  These drugs should be administered cautiously in patients with reduced renal function and a dose adjustment might be required depending on the level of impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28722, 30387, 'Topiramate', 'Kidney Diseases', 'The major route of elimination of carbonic anhydrase inhibitors is through the kidney.  These drugs should be administered cautiously in patients with reduced renal function and a dose adjustment might be required depending on the level of impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28723, 3025, 'Topiramate', 'Acidosis', 'Reduced plasma bicarbonate levels and, in some instances, elevated plasma chloride levels may result in metabolic acidosis during long-term therapy with carbonic anhydrase inhibitors.  Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with metabolic or hyperchloremic acidosis or with conditions that predispose to acidosis (renal disease, severe respiratory disorders, diarrhea).  The measurement of baseline and periodic serum bicarbonate is recommended.  If metabolic acidosis develops (it may be corrected by administration of sodium bicarbonate), and persists, a dose reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28724, 3026, 'Topiramate', 'Acidosis', 'Reduced plasma bicarbonate levels and, in some instances, elevated plasma chloride levels may result in metabolic acidosis during long-term therapy with carbonic anhydrase inhibitors.  Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with metabolic or hyperchloremic acidosis or with conditions that predispose to acidosis (renal disease, severe respiratory disorders, diarrhea).  The measurement of baseline and periodic serum bicarbonate is recommended.  If metabolic acidosis develops (it may be corrected by administration of sodium bicarbonate), and persists, a dose reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28725, 8555, 'Topiramate', 'Acidosis', 'Reduced plasma bicarbonate levels and, in some instances, elevated plasma chloride levels may result in metabolic acidosis during long-term therapy with carbonic anhydrase inhibitors.  Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with metabolic or hyperchloremic acidosis or with conditions that predispose to acidosis (renal disease, severe respiratory disorders, diarrhea).  The measurement of baseline and periodic serum bicarbonate is recommended.  If metabolic acidosis develops (it may be corrected by administration of sodium bicarbonate), and persists, a dose reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28726, 11537, 'Topiramate', 'Acidosis', 'Reduced plasma bicarbonate levels and, in some instances, elevated plasma chloride levels may result in metabolic acidosis during long-term therapy with carbonic anhydrase inhibitors.  Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with metabolic or hyperchloremic acidosis or with conditions that predispose to acidosis (renal disease, severe respiratory disorders, diarrhea).  The measurement of baseline and periodic serum bicarbonate is recommended.  If metabolic acidosis develops (it may be corrected by administration of sodium bicarbonate), and persists, a dose reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28727, 16780, 'Topiramate', 'Acidosis', 'Reduced plasma bicarbonate levels and, in some instances, elevated plasma chloride levels may result in metabolic acidosis during long-term therapy with carbonic anhydrase inhibitors.  Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with metabolic or hyperchloremic acidosis or with conditions that predispose to acidosis (renal disease, severe respiratory disorders, diarrhea).  The measurement of baseline and periodic serum bicarbonate is recommended.  If metabolic acidosis develops (it may be corrected by administration of sodium bicarbonate), and persists, a dose reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28728, 17218, 'Topiramate', 'Acidosis', 'Reduced plasma bicarbonate levels and, in some instances, elevated plasma chloride levels may result in metabolic acidosis during long-term therapy with carbonic anhydrase inhibitors.  Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with metabolic or hyperchloremic acidosis or with conditions that predispose to acidosis (renal disease, severe respiratory disorders, diarrhea).  The measurement of baseline and periodic serum bicarbonate is recommended.  If metabolic acidosis develops (it may be corrected by administration of sodium bicarbonate), and persists, a dose reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28729, 18427, 'Topiramate', 'Acidosis', 'Reduced plasma bicarbonate levels and, in some instances, elevated plasma chloride levels may result in metabolic acidosis during long-term therapy with carbonic anhydrase inhibitors.  Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with metabolic or hyperchloremic acidosis or with conditions that predispose to acidosis (renal disease, severe respiratory disorders, diarrhea).  The measurement of baseline and periodic serum bicarbonate is recommended.  If metabolic acidosis develops (it may be corrected by administration of sodium bicarbonate), and persists, a dose reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28730, 18428, 'Topiramate', 'Acidosis', 'Reduced plasma bicarbonate levels and, in some instances, elevated plasma chloride levels may result in metabolic acidosis during long-term therapy with carbonic anhydrase inhibitors.  Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with metabolic or hyperchloremic acidosis or with conditions that predispose to acidosis (renal disease, severe respiratory disorders, diarrhea).  The measurement of baseline and periodic serum bicarbonate is recommended.  If metabolic acidosis develops (it may be corrected by administration of sodium bicarbonate), and persists, a dose reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28731, 18429, 'Topiramate', 'Acidosis', 'Reduced plasma bicarbonate levels and, in some instances, elevated plasma chloride levels may result in metabolic acidosis during long-term therapy with carbonic anhydrase inhibitors.  Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with metabolic or hyperchloremic acidosis or with conditions that predispose to acidosis (renal disease, severe respiratory disorders, diarrhea).  The measurement of baseline and periodic serum bicarbonate is recommended.  If metabolic acidosis develops (it may be corrected by administration of sodium bicarbonate), and persists, a dose reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28732, 27427, 'Topiramate', 'Acidosis', 'Reduced plasma bicarbonate levels and, in some instances, elevated plasma chloride levels may result in metabolic acidosis during long-term therapy with carbonic anhydrase inhibitors.  Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with metabolic or hyperchloremic acidosis or with conditions that predispose to acidosis (renal disease, severe respiratory disorders, diarrhea).  The measurement of baseline and periodic serum bicarbonate is recommended.  If metabolic acidosis develops (it may be corrected by administration of sodium bicarbonate), and persists, a dose reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28733, 27428, 'Topiramate', 'Acidosis', 'Reduced plasma bicarbonate levels and, in some instances, elevated plasma chloride levels may result in metabolic acidosis during long-term therapy with carbonic anhydrase inhibitors.  Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with metabolic or hyperchloremic acidosis or with conditions that predispose to acidosis (renal disease, severe respiratory disorders, diarrhea).  The measurement of baseline and periodic serum bicarbonate is recommended.  If metabolic acidosis develops (it may be corrected by administration of sodium bicarbonate), and persists, a dose reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28734, 27429, 'Topiramate', 'Acidosis', 'Reduced plasma bicarbonate levels and, in some instances, elevated plasma chloride levels may result in metabolic acidosis during long-term therapy with carbonic anhydrase inhibitors.  Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with metabolic or hyperchloremic acidosis or with conditions that predispose to acidosis (renal disease, severe respiratory disorders, diarrhea).  The measurement of baseline and periodic serum bicarbonate is recommended.  If metabolic acidosis develops (it may be corrected by administration of sodium bicarbonate), and persists, a dose reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28735, 28295, 'Topiramate', 'Acidosis', 'Reduced plasma bicarbonate levels and, in some instances, elevated plasma chloride levels may result in metabolic acidosis during long-term therapy with carbonic anhydrase inhibitors.  Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with metabolic or hyperchloremic acidosis or with conditions that predispose to acidosis (renal disease, severe respiratory disorders, diarrhea).  The measurement of baseline and periodic serum bicarbonate is recommended.  If metabolic acidosis develops (it may be corrected by administration of sodium bicarbonate), and persists, a dose reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28736, 28296, 'Topiramate', 'Acidosis', 'Reduced plasma bicarbonate levels and, in some instances, elevated plasma chloride levels may result in metabolic acidosis during long-term therapy with carbonic anhydrase inhibitors.  Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with metabolic or hyperchloremic acidosis or with conditions that predispose to acidosis (renal disease, severe respiratory disorders, diarrhea).  The measurement of baseline and periodic serum bicarbonate is recommended.  If metabolic acidosis develops (it may be corrected by administration of sodium bicarbonate), and persists, a dose reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28737, 28297, 'Topiramate', 'Acidosis', 'Reduced plasma bicarbonate levels and, in some instances, elevated plasma chloride levels may result in metabolic acidosis during long-term therapy with carbonic anhydrase inhibitors.  Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with metabolic or hyperchloremic acidosis or with conditions that predispose to acidosis (renal disease, severe respiratory disorders, diarrhea).  The measurement of baseline and periodic serum bicarbonate is recommended.  If metabolic acidosis develops (it may be corrected by administration of sodium bicarbonate), and persists, a dose reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28738, 28298, 'Topiramate', 'Acidosis', 'Reduced plasma bicarbonate levels and, in some instances, elevated plasma chloride levels may result in metabolic acidosis during long-term therapy with carbonic anhydrase inhibitors.  Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with metabolic or hyperchloremic acidosis or with conditions that predispose to acidosis (renal disease, severe respiratory disorders, diarrhea).  The measurement of baseline and periodic serum bicarbonate is recommended.  If metabolic acidosis develops (it may be corrected by administration of sodium bicarbonate), and persists, a dose reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28739, 28329, 'Topiramate', 'Acidosis', 'Reduced plasma bicarbonate levels and, in some instances, elevated plasma chloride levels may result in metabolic acidosis during long-term therapy with carbonic anhydrase inhibitors.  Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with metabolic or hyperchloremic acidosis or with conditions that predispose to acidosis (renal disease, severe respiratory disorders, diarrhea).  The measurement of baseline and periodic serum bicarbonate is recommended.  If metabolic acidosis develops (it may be corrected by administration of sodium bicarbonate), and persists, a dose reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28740, 28330, 'Topiramate', 'Acidosis', 'Reduced plasma bicarbonate levels and, in some instances, elevated plasma chloride levels may result in metabolic acidosis during long-term therapy with carbonic anhydrase inhibitors.  Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with metabolic or hyperchloremic acidosis or with conditions that predispose to acidosis (renal disease, severe respiratory disorders, diarrhea).  The measurement of baseline and periodic serum bicarbonate is recommended.  If metabolic acidosis develops (it may be corrected by administration of sodium bicarbonate), and persists, a dose reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28741, 28333, 'Topiramate', 'Acidosis', 'Reduced plasma bicarbonate levels and, in some instances, elevated plasma chloride levels may result in metabolic acidosis during long-term therapy with carbonic anhydrase inhibitors.  Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with metabolic or hyperchloremic acidosis or with conditions that predispose to acidosis (renal disease, severe respiratory disorders, diarrhea).  The measurement of baseline and periodic serum bicarbonate is recommended.  If metabolic acidosis develops (it may be corrected by administration of sodium bicarbonate), and persists, a dose reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28742, 28334, 'Topiramate', 'Acidosis', 'Reduced plasma bicarbonate levels and, in some instances, elevated plasma chloride levels may result in metabolic acidosis during long-term therapy with carbonic anhydrase inhibitors.  Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with metabolic or hyperchloremic acidosis or with conditions that predispose to acidosis (renal disease, severe respiratory disorders, diarrhea).  The measurement of baseline and periodic serum bicarbonate is recommended.  If metabolic acidosis develops (it may be corrected by administration of sodium bicarbonate), and persists, a dose reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28743, 28339, 'Topiramate', 'Acidosis', 'Reduced plasma bicarbonate levels and, in some instances, elevated plasma chloride levels may result in metabolic acidosis during long-term therapy with carbonic anhydrase inhibitors.  Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with metabolic or hyperchloremic acidosis or with conditions that predispose to acidosis (renal disease, severe respiratory disorders, diarrhea).  The measurement of baseline and periodic serum bicarbonate is recommended.  If metabolic acidosis develops (it may be corrected by administration of sodium bicarbonate), and persists, a dose reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28744, 30387, 'Topiramate', 'Acidosis', 'Reduced plasma bicarbonate levels and, in some instances, elevated plasma chloride levels may result in metabolic acidosis during long-term therapy with carbonic anhydrase inhibitors.  Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with metabolic or hyperchloremic acidosis or with conditions that predispose to acidosis (renal disease, severe respiratory disorders, diarrhea).  The measurement of baseline and periodic serum bicarbonate is recommended.  If metabolic acidosis develops (it may be corrected by administration of sodium bicarbonate), and persists, a dose reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28745, 3025, 'Topiramate', 'Glaucoma, Angle-Closure', 'A syndrome consisting of acute myopia associated with secondary angle closure glaucoma has been reported in patients receiving topiramate.  Symptoms include acute onset of visual acuity and/or ocular pain.  It typically occurs within 1 month of treatment initiation and it has been reported in both pediatric and adult patients.  Caution is recommended when prescribing topiramate in patients with elevated intraocular pressure regardless of the etiology.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28746, 3026, 'Topiramate', 'Glaucoma, Angle-Closure', 'A syndrome consisting of acute myopia associated with secondary angle closure glaucoma has been reported in patients receiving topiramate.  Symptoms include acute onset of visual acuity and/or ocular pain.  It typically occurs within 1 month of treatment initiation and it has been reported in both pediatric and adult patients.  Caution is recommended when prescribing topiramate in patients with elevated intraocular pressure regardless of the etiology.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28747, 8555, 'Topiramate', 'Glaucoma, Angle-Closure', 'A syndrome consisting of acute myopia associated with secondary angle closure glaucoma has been reported in patients receiving topiramate.  Symptoms include acute onset of visual acuity and/or ocular pain.  It typically occurs within 1 month of treatment initiation and it has been reported in both pediatric and adult patients.  Caution is recommended when prescribing topiramate in patients with elevated intraocular pressure regardless of the etiology.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28748, 11537, 'Topiramate', 'Glaucoma, Angle-Closure', 'A syndrome consisting of acute myopia associated with secondary angle closure glaucoma has been reported in patients receiving topiramate.  Symptoms include acute onset of visual acuity and/or ocular pain.  It typically occurs within 1 month of treatment initiation and it has been reported in both pediatric and adult patients.  Caution is recommended when prescribing topiramate in patients with elevated intraocular pressure regardless of the etiology.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28749, 16780, 'Topiramate', 'Glaucoma, Angle-Closure', 'A syndrome consisting of acute myopia associated with secondary angle closure glaucoma has been reported in patients receiving topiramate.  Symptoms include acute onset of visual acuity and/or ocular pain.  It typically occurs within 1 month of treatment initiation and it has been reported in both pediatric and adult patients.  Caution is recommended when prescribing topiramate in patients with elevated intraocular pressure regardless of the etiology.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28750, 17218, 'Topiramate', 'Glaucoma, Angle-Closure', 'A syndrome consisting of acute myopia associated with secondary angle closure glaucoma has been reported in patients receiving topiramate.  Symptoms include acute onset of visual acuity and/or ocular pain.  It typically occurs within 1 month of treatment initiation and it has been reported in both pediatric and adult patients.  Caution is recommended when prescribing topiramate in patients with elevated intraocular pressure regardless of the etiology.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28751, 18427, 'Topiramate', 'Glaucoma, Angle-Closure', 'A syndrome consisting of acute myopia associated with secondary angle closure glaucoma has been reported in patients receiving topiramate.  Symptoms include acute onset of visual acuity and/or ocular pain.  It typically occurs within 1 month of treatment initiation and it has been reported in both pediatric and adult patients.  Caution is recommended when prescribing topiramate in patients with elevated intraocular pressure regardless of the etiology.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28752, 18428, 'Topiramate', 'Glaucoma, Angle-Closure', 'A syndrome consisting of acute myopia associated with secondary angle closure glaucoma has been reported in patients receiving topiramate.  Symptoms include acute onset of visual acuity and/or ocular pain.  It typically occurs within 1 month of treatment initiation and it has been reported in both pediatric and adult patients.  Caution is recommended when prescribing topiramate in patients with elevated intraocular pressure regardless of the etiology.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28753, 18429, 'Topiramate', 'Glaucoma, Angle-Closure', 'A syndrome consisting of acute myopia associated with secondary angle closure glaucoma has been reported in patients receiving topiramate.  Symptoms include acute onset of visual acuity and/or ocular pain.  It typically occurs within 1 month of treatment initiation and it has been reported in both pediatric and adult patients.  Caution is recommended when prescribing topiramate in patients with elevated intraocular pressure regardless of the etiology.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28754, 27427, 'Topiramate', 'Glaucoma, Angle-Closure', 'A syndrome consisting of acute myopia associated with secondary angle closure glaucoma has been reported in patients receiving topiramate.  Symptoms include acute onset of visual acuity and/or ocular pain.  It typically occurs within 1 month of treatment initiation and it has been reported in both pediatric and adult patients.  Caution is recommended when prescribing topiramate in patients with elevated intraocular pressure regardless of the etiology.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28755, 27428, 'Topiramate', 'Glaucoma, Angle-Closure', 'A syndrome consisting of acute myopia associated with secondary angle closure glaucoma has been reported in patients receiving topiramate.  Symptoms include acute onset of visual acuity and/or ocular pain.  It typically occurs within 1 month of treatment initiation and it has been reported in both pediatric and adult patients.  Caution is recommended when prescribing topiramate in patients with elevated intraocular pressure regardless of the etiology.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28756, 27429, 'Topiramate', 'Glaucoma, Angle-Closure', 'A syndrome consisting of acute myopia associated with secondary angle closure glaucoma has been reported in patients receiving topiramate.  Symptoms include acute onset of visual acuity and/or ocular pain.  It typically occurs within 1 month of treatment initiation and it has been reported in both pediatric and adult patients.  Caution is recommended when prescribing topiramate in patients with elevated intraocular pressure regardless of the etiology.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28757, 28295, 'Topiramate', 'Glaucoma, Angle-Closure', 'A syndrome consisting of acute myopia associated with secondary angle closure glaucoma has been reported in patients receiving topiramate.  Symptoms include acute onset of visual acuity and/or ocular pain.  It typically occurs within 1 month of treatment initiation and it has been reported in both pediatric and adult patients.  Caution is recommended when prescribing topiramate in patients with elevated intraocular pressure regardless of the etiology.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28758, 28296, 'Topiramate', 'Glaucoma, Angle-Closure', 'A syndrome consisting of acute myopia associated with secondary angle closure glaucoma has been reported in patients receiving topiramate.  Symptoms include acute onset of visual acuity and/or ocular pain.  It typically occurs within 1 month of treatment initiation and it has been reported in both pediatric and adult patients.  Caution is recommended when prescribing topiramate in patients with elevated intraocular pressure regardless of the etiology.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28759, 28297, 'Topiramate', 'Glaucoma, Angle-Closure', 'A syndrome consisting of acute myopia associated with secondary angle closure glaucoma has been reported in patients receiving topiramate.  Symptoms include acute onset of visual acuity and/or ocular pain.  It typically occurs within 1 month of treatment initiation and it has been reported in both pediatric and adult patients.  Caution is recommended when prescribing topiramate in patients with elevated intraocular pressure regardless of the etiology.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28760, 28298, 'Topiramate', 'Glaucoma, Angle-Closure', 'A syndrome consisting of acute myopia associated with secondary angle closure glaucoma has been reported in patients receiving topiramate.  Symptoms include acute onset of visual acuity and/or ocular pain.  It typically occurs within 1 month of treatment initiation and it has been reported in both pediatric and adult patients.  Caution is recommended when prescribing topiramate in patients with elevated intraocular pressure regardless of the etiology.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28761, 28329, 'Topiramate', 'Glaucoma, Angle-Closure', 'A syndrome consisting of acute myopia associated with secondary angle closure glaucoma has been reported in patients receiving topiramate.  Symptoms include acute onset of visual acuity and/or ocular pain.  It typically occurs within 1 month of treatment initiation and it has been reported in both pediatric and adult patients.  Caution is recommended when prescribing topiramate in patients with elevated intraocular pressure regardless of the etiology.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28762, 28330, 'Topiramate', 'Glaucoma, Angle-Closure', 'A syndrome consisting of acute myopia associated with secondary angle closure glaucoma has been reported in patients receiving topiramate.  Symptoms include acute onset of visual acuity and/or ocular pain.  It typically occurs within 1 month of treatment initiation and it has been reported in both pediatric and adult patients.  Caution is recommended when prescribing topiramate in patients with elevated intraocular pressure regardless of the etiology.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28763, 28333, 'Topiramate', 'Glaucoma, Angle-Closure', 'A syndrome consisting of acute myopia associated with secondary angle closure glaucoma has been reported in patients receiving topiramate.  Symptoms include acute onset of visual acuity and/or ocular pain.  It typically occurs within 1 month of treatment initiation and it has been reported in both pediatric and adult patients.  Caution is recommended when prescribing topiramate in patients with elevated intraocular pressure regardless of the etiology.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28764, 28334, 'Topiramate', 'Glaucoma, Angle-Closure', 'A syndrome consisting of acute myopia associated with secondary angle closure glaucoma has been reported in patients receiving topiramate.  Symptoms include acute onset of visual acuity and/or ocular pain.  It typically occurs within 1 month of treatment initiation and it has been reported in both pediatric and adult patients.  Caution is recommended when prescribing topiramate in patients with elevated intraocular pressure regardless of the etiology.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28765, 28339, 'Topiramate', 'Glaucoma, Angle-Closure', 'A syndrome consisting of acute myopia associated with secondary angle closure glaucoma has been reported in patients receiving topiramate.  Symptoms include acute onset of visual acuity and/or ocular pain.  It typically occurs within 1 month of treatment initiation and it has been reported in both pediatric and adult patients.  Caution is recommended when prescribing topiramate in patients with elevated intraocular pressure regardless of the etiology.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28766, 30387, 'Topiramate', 'Glaucoma, Angle-Closure', 'A syndrome consisting of acute myopia associated with secondary angle closure glaucoma has been reported in patients receiving topiramate.  Symptoms include acute onset of visual acuity and/or ocular pain.  It typically occurs within 1 month of treatment initiation and it has been reported in both pediatric and adult patients.  Caution is recommended when prescribing topiramate in patients with elevated intraocular pressure regardless of the etiology.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28767, 3025, 'Topiramate', 'Diseases requiring hemodialysis', 'Topiramate is cleared by hemodialysis at a rate that is 4 to 6 times greater than that in a normal individual.  A prolonged period of dialysis may cause plasma topiramate level to fall below that required to maintain an anti-seizure effect, thus a supplemental dose may be required in patients undergoing hemodialysis.  The actual adjustment should take into account the duration of dialysis, the clearance rate of the dialysis system being used, and the effective renal clearance of topiramate in the patient being dialyzed.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28768, 3026, 'Topiramate', 'Diseases requiring hemodialysis', 'Topiramate is cleared by hemodialysis at a rate that is 4 to 6 times greater than that in a normal individual.  A prolonged period of dialysis may cause plasma topiramate level to fall below that required to maintain an anti-seizure effect, thus a supplemental dose may be required in patients undergoing hemodialysis.  The actual adjustment should take into account the duration of dialysis, the clearance rate of the dialysis system being used, and the effective renal clearance of topiramate in the patient being dialyzed.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28769, 8555, 'Topiramate', 'Diseases requiring hemodialysis', 'Topiramate is cleared by hemodialysis at a rate that is 4 to 6 times greater than that in a normal individual.  A prolonged period of dialysis may cause plasma topiramate level to fall below that required to maintain an anti-seizure effect, thus a supplemental dose may be required in patients undergoing hemodialysis.  The actual adjustment should take into account the duration of dialysis, the clearance rate of the dialysis system being used, and the effective renal clearance of topiramate in the patient being dialyzed.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28770, 11537, 'Topiramate', 'Diseases requiring hemodialysis', 'Topiramate is cleared by hemodialysis at a rate that is 4 to 6 times greater than that in a normal individual.  A prolonged period of dialysis may cause plasma topiramate level to fall below that required to maintain an anti-seizure effect, thus a supplemental dose may be required in patients undergoing hemodialysis.  The actual adjustment should take into account the duration of dialysis, the clearance rate of the dialysis system being used, and the effective renal clearance of topiramate in the patient being dialyzed.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28771, 16780, 'Topiramate', 'Diseases requiring hemodialysis', 'Topiramate is cleared by hemodialysis at a rate that is 4 to 6 times greater than that in a normal individual.  A prolonged period of dialysis may cause plasma topiramate level to fall below that required to maintain an anti-seizure effect, thus a supplemental dose may be required in patients undergoing hemodialysis.  The actual adjustment should take into account the duration of dialysis, the clearance rate of the dialysis system being used, and the effective renal clearance of topiramate in the patient being dialyzed.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28772, 17218, 'Topiramate', 'Diseases requiring hemodialysis', 'Topiramate is cleared by hemodialysis at a rate that is 4 to 6 times greater than that in a normal individual.  A prolonged period of dialysis may cause plasma topiramate level to fall below that required to maintain an anti-seizure effect, thus a supplemental dose may be required in patients undergoing hemodialysis.  The actual adjustment should take into account the duration of dialysis, the clearance rate of the dialysis system being used, and the effective renal clearance of topiramate in the patient being dialyzed.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28773, 18427, 'Topiramate', 'Diseases requiring hemodialysis', 'Topiramate is cleared by hemodialysis at a rate that is 4 to 6 times greater than that in a normal individual.  A prolonged period of dialysis may cause plasma topiramate level to fall below that required to maintain an anti-seizure effect, thus a supplemental dose may be required in patients undergoing hemodialysis.  The actual adjustment should take into account the duration of dialysis, the clearance rate of the dialysis system being used, and the effective renal clearance of topiramate in the patient being dialyzed.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28774, 18428, 'Topiramate', 'Diseases requiring hemodialysis', 'Topiramate is cleared by hemodialysis at a rate that is 4 to 6 times greater than that in a normal individual.  A prolonged period of dialysis may cause plasma topiramate level to fall below that required to maintain an anti-seizure effect, thus a supplemental dose may be required in patients undergoing hemodialysis.  The actual adjustment should take into account the duration of dialysis, the clearance rate of the dialysis system being used, and the effective renal clearance of topiramate in the patient being dialyzed.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28775, 18429, 'Topiramate', 'Diseases requiring hemodialysis', 'Topiramate is cleared by hemodialysis at a rate that is 4 to 6 times greater than that in a normal individual.  A prolonged period of dialysis may cause plasma topiramate level to fall below that required to maintain an anti-seizure effect, thus a supplemental dose may be required in patients undergoing hemodialysis.  The actual adjustment should take into account the duration of dialysis, the clearance rate of the dialysis system being used, and the effective renal clearance of topiramate in the patient being dialyzed.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28776, 27427, 'Topiramate', 'Diseases requiring hemodialysis', 'Topiramate is cleared by hemodialysis at a rate that is 4 to 6 times greater than that in a normal individual.  A prolonged period of dialysis may cause plasma topiramate level to fall below that required to maintain an anti-seizure effect, thus a supplemental dose may be required in patients undergoing hemodialysis.  The actual adjustment should take into account the duration of dialysis, the clearance rate of the dialysis system being used, and the effective renal clearance of topiramate in the patient being dialyzed.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28777, 27428, 'Topiramate', 'Diseases requiring hemodialysis', 'Topiramate is cleared by hemodialysis at a rate that is 4 to 6 times greater than that in a normal individual.  A prolonged period of dialysis may cause plasma topiramate level to fall below that required to maintain an anti-seizure effect, thus a supplemental dose may be required in patients undergoing hemodialysis.  The actual adjustment should take into account the duration of dialysis, the clearance rate of the dialysis system being used, and the effective renal clearance of topiramate in the patient being dialyzed.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28778, 27429, 'Topiramate', 'Diseases requiring hemodialysis', 'Topiramate is cleared by hemodialysis at a rate that is 4 to 6 times greater than that in a normal individual.  A prolonged period of dialysis may cause plasma topiramate level to fall below that required to maintain an anti-seizure effect, thus a supplemental dose may be required in patients undergoing hemodialysis.  The actual adjustment should take into account the duration of dialysis, the clearance rate of the dialysis system being used, and the effective renal clearance of topiramate in the patient being dialyzed.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28779, 28295, 'Topiramate', 'Diseases requiring hemodialysis', 'Topiramate is cleared by hemodialysis at a rate that is 4 to 6 times greater than that in a normal individual.  A prolonged period of dialysis may cause plasma topiramate level to fall below that required to maintain an anti-seizure effect, thus a supplemental dose may be required in patients undergoing hemodialysis.  The actual adjustment should take into account the duration of dialysis, the clearance rate of the dialysis system being used, and the effective renal clearance of topiramate in the patient being dialyzed.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28780, 28296, 'Topiramate', 'Diseases requiring hemodialysis', 'Topiramate is cleared by hemodialysis at a rate that is 4 to 6 times greater than that in a normal individual.  A prolonged period of dialysis may cause plasma topiramate level to fall below that required to maintain an anti-seizure effect, thus a supplemental dose may be required in patients undergoing hemodialysis.  The actual adjustment should take into account the duration of dialysis, the clearance rate of the dialysis system being used, and the effective renal clearance of topiramate in the patient being dialyzed.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28781, 28297, 'Topiramate', 'Diseases requiring hemodialysis', 'Topiramate is cleared by hemodialysis at a rate that is 4 to 6 times greater than that in a normal individual.  A prolonged period of dialysis may cause plasma topiramate level to fall below that required to maintain an anti-seizure effect, thus a supplemental dose may be required in patients undergoing hemodialysis.  The actual adjustment should take into account the duration of dialysis, the clearance rate of the dialysis system being used, and the effective renal clearance of topiramate in the patient being dialyzed.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28782, 28298, 'Topiramate', 'Diseases requiring hemodialysis', 'Topiramate is cleared by hemodialysis at a rate that is 4 to 6 times greater than that in a normal individual.  A prolonged period of dialysis may cause plasma topiramate level to fall below that required to maintain an anti-seizure effect, thus a supplemental dose may be required in patients undergoing hemodialysis.  The actual adjustment should take into account the duration of dialysis, the clearance rate of the dialysis system being used, and the effective renal clearance of topiramate in the patient being dialyzed.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28783, 28329, 'Topiramate', 'Diseases requiring hemodialysis', 'Topiramate is cleared by hemodialysis at a rate that is 4 to 6 times greater than that in a normal individual.  A prolonged period of dialysis may cause plasma topiramate level to fall below that required to maintain an anti-seizure effect, thus a supplemental dose may be required in patients undergoing hemodialysis.  The actual adjustment should take into account the duration of dialysis, the clearance rate of the dialysis system being used, and the effective renal clearance of topiramate in the patient being dialyzed.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28784, 28330, 'Topiramate', 'Diseases requiring hemodialysis', 'Topiramate is cleared by hemodialysis at a rate that is 4 to 6 times greater than that in a normal individual.  A prolonged period of dialysis may cause plasma topiramate level to fall below that required to maintain an anti-seizure effect, thus a supplemental dose may be required in patients undergoing hemodialysis.  The actual adjustment should take into account the duration of dialysis, the clearance rate of the dialysis system being used, and the effective renal clearance of topiramate in the patient being dialyzed.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28785, 28333, 'Topiramate', 'Diseases requiring hemodialysis', 'Topiramate is cleared by hemodialysis at a rate that is 4 to 6 times greater than that in a normal individual.  A prolonged period of dialysis may cause plasma topiramate level to fall below that required to maintain an anti-seizure effect, thus a supplemental dose may be required in patients undergoing hemodialysis.  The actual adjustment should take into account the duration of dialysis, the clearance rate of the dialysis system being used, and the effective renal clearance of topiramate in the patient being dialyzed.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28786, 28334, 'Topiramate', 'Diseases requiring hemodialysis', 'Topiramate is cleared by hemodialysis at a rate that is 4 to 6 times greater than that in a normal individual.  A prolonged period of dialysis may cause plasma topiramate level to fall below that required to maintain an anti-seizure effect, thus a supplemental dose may be required in patients undergoing hemodialysis.  The actual adjustment should take into account the duration of dialysis, the clearance rate of the dialysis system being used, and the effective renal clearance of topiramate in the patient being dialyzed.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28787, 28339, 'Topiramate', 'Diseases requiring hemodialysis', 'Topiramate is cleared by hemodialysis at a rate that is 4 to 6 times greater than that in a normal individual.  A prolonged period of dialysis may cause plasma topiramate level to fall below that required to maintain an anti-seizure effect, thus a supplemental dose may be required in patients undergoing hemodialysis.  The actual adjustment should take into account the duration of dialysis, the clearance rate of the dialysis system being used, and the effective renal clearance of topiramate in the patient being dialyzed.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28788, 30387, 'Topiramate', 'Diseases requiring hemodialysis', 'Topiramate is cleared by hemodialysis at a rate that is 4 to 6 times greater than that in a normal individual.  A prolonged period of dialysis may cause plasma topiramate level to fall below that required to maintain an anti-seizure effect, thus a supplemental dose may be required in patients undergoing hemodialysis.  The actual adjustment should take into account the duration of dialysis, the clearance rate of the dialysis system being used, and the effective renal clearance of topiramate in the patient being dialyzed.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28789, 3025, 'Topiramate', 'Nephrolithiasis', 'The use of topiramate may infrequently be associated with the development of kidney stones.  The reported incidence was 1.5% (32 of 2,086 patients) during premarketing use, which is about 2 to 4 times that expected in a similar, untreated population.  Topiramate is a weak carbonic anhydrase inhibitor and may promote stone formation by reducing urinary citrate excretion and increasing urinary pH.  Therapy with topiramate should be administered cautiously with adequate hydration in patients with a history of nephrolithiasis.  The concomitant use of topiramate with other carbonic anhydrase inhibitors should be avoided.  Patients who are dehydrated may be at increased risk for the development of nephrolithiasis and should be encouraged to consume additional amounts of liquid during topiramate therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28790, 3026, 'Topiramate', 'Nephrolithiasis', 'The use of topiramate may infrequently be associated with the development of kidney stones.  The reported incidence was 1.5% (32 of 2,086 patients) during premarketing use, which is about 2 to 4 times that expected in a similar, untreated population.  Topiramate is a weak carbonic anhydrase inhibitor and may promote stone formation by reducing urinary citrate excretion and increasing urinary pH.  Therapy with topiramate should be administered cautiously with adequate hydration in patients with a history of nephrolithiasis.  The concomitant use of topiramate with other carbonic anhydrase inhibitors should be avoided.  Patients who are dehydrated may be at increased risk for the development of nephrolithiasis and should be encouraged to consume additional amounts of liquid during topiramate therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28791, 8555, 'Topiramate', 'Nephrolithiasis', 'The use of topiramate may infrequently be associated with the development of kidney stones.  The reported incidence was 1.5% (32 of 2,086 patients) during premarketing use, which is about 2 to 4 times that expected in a similar, untreated population.  Topiramate is a weak carbonic anhydrase inhibitor and may promote stone formation by reducing urinary citrate excretion and increasing urinary pH.  Therapy with topiramate should be administered cautiously with adequate hydration in patients with a history of nephrolithiasis.  The concomitant use of topiramate with other carbonic anhydrase inhibitors should be avoided.  Patients who are dehydrated may be at increased risk for the development of nephrolithiasis and should be encouraged to consume additional amounts of liquid during topiramate therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28792, 11537, 'Topiramate', 'Nephrolithiasis', 'The use of topiramate may infrequently be associated with the development of kidney stones.  The reported incidence was 1.5% (32 of 2,086 patients) during premarketing use, which is about 2 to 4 times that expected in a similar, untreated population.  Topiramate is a weak carbonic anhydrase inhibitor and may promote stone formation by reducing urinary citrate excretion and increasing urinary pH.  Therapy with topiramate should be administered cautiously with adequate hydration in patients with a history of nephrolithiasis.  The concomitant use of topiramate with other carbonic anhydrase inhibitors should be avoided.  Patients who are dehydrated may be at increased risk for the development of nephrolithiasis and should be encouraged to consume additional amounts of liquid during topiramate therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28793, 16780, 'Topiramate', 'Nephrolithiasis', 'The use of topiramate may infrequently be associated with the development of kidney stones.  The reported incidence was 1.5% (32 of 2,086 patients) during premarketing use, which is about 2 to 4 times that expected in a similar, untreated population.  Topiramate is a weak carbonic anhydrase inhibitor and may promote stone formation by reducing urinary citrate excretion and increasing urinary pH.  Therapy with topiramate should be administered cautiously with adequate hydration in patients with a history of nephrolithiasis.  The concomitant use of topiramate with other carbonic anhydrase inhibitors should be avoided.  Patients who are dehydrated may be at increased risk for the development of nephrolithiasis and should be encouraged to consume additional amounts of liquid during topiramate therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28794, 17218, 'Topiramate', 'Nephrolithiasis', 'The use of topiramate may infrequently be associated with the development of kidney stones.  The reported incidence was 1.5% (32 of 2,086 patients) during premarketing use, which is about 2 to 4 times that expected in a similar, untreated population.  Topiramate is a weak carbonic anhydrase inhibitor and may promote stone formation by reducing urinary citrate excretion and increasing urinary pH.  Therapy with topiramate should be administered cautiously with adequate hydration in patients with a history of nephrolithiasis.  The concomitant use of topiramate with other carbonic anhydrase inhibitors should be avoided.  Patients who are dehydrated may be at increased risk for the development of nephrolithiasis and should be encouraged to consume additional amounts of liquid during topiramate therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28795, 18427, 'Topiramate', 'Nephrolithiasis', 'The use of topiramate may infrequently be associated with the development of kidney stones.  The reported incidence was 1.5% (32 of 2,086 patients) during premarketing use, which is about 2 to 4 times that expected in a similar, untreated population.  Topiramate is a weak carbonic anhydrase inhibitor and may promote stone formation by reducing urinary citrate excretion and increasing urinary pH.  Therapy with topiramate should be administered cautiously with adequate hydration in patients with a history of nephrolithiasis.  The concomitant use of topiramate with other carbonic anhydrase inhibitors should be avoided.  Patients who are dehydrated may be at increased risk for the development of nephrolithiasis and should be encouraged to consume additional amounts of liquid during topiramate therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28796, 18428, 'Topiramate', 'Nephrolithiasis', 'The use of topiramate may infrequently be associated with the development of kidney stones.  The reported incidence was 1.5% (32 of 2,086 patients) during premarketing use, which is about 2 to 4 times that expected in a similar, untreated population.  Topiramate is a weak carbonic anhydrase inhibitor and may promote stone formation by reducing urinary citrate excretion and increasing urinary pH.  Therapy with topiramate should be administered cautiously with adequate hydration in patients with a history of nephrolithiasis.  The concomitant use of topiramate with other carbonic anhydrase inhibitors should be avoided.  Patients who are dehydrated may be at increased risk for the development of nephrolithiasis and should be encouraged to consume additional amounts of liquid during topiramate therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28797, 18429, 'Topiramate', 'Nephrolithiasis', 'The use of topiramate may infrequently be associated with the development of kidney stones.  The reported incidence was 1.5% (32 of 2,086 patients) during premarketing use, which is about 2 to 4 times that expected in a similar, untreated population.  Topiramate is a weak carbonic anhydrase inhibitor and may promote stone formation by reducing urinary citrate excretion and increasing urinary pH.  Therapy with topiramate should be administered cautiously with adequate hydration in patients with a history of nephrolithiasis.  The concomitant use of topiramate with other carbonic anhydrase inhibitors should be avoided.  Patients who are dehydrated may be at increased risk for the development of nephrolithiasis and should be encouraged to consume additional amounts of liquid during topiramate therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28798, 27427, 'Topiramate', 'Nephrolithiasis', 'The use of topiramate may infrequently be associated with the development of kidney stones.  The reported incidence was 1.5% (32 of 2,086 patients) during premarketing use, which is about 2 to 4 times that expected in a similar, untreated population.  Topiramate is a weak carbonic anhydrase inhibitor and may promote stone formation by reducing urinary citrate excretion and increasing urinary pH.  Therapy with topiramate should be administered cautiously with adequate hydration in patients with a history of nephrolithiasis.  The concomitant use of topiramate with other carbonic anhydrase inhibitors should be avoided.  Patients who are dehydrated may be at increased risk for the development of nephrolithiasis and should be encouraged to consume additional amounts of liquid during topiramate therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28799, 27428, 'Topiramate', 'Nephrolithiasis', 'The use of topiramate may infrequently be associated with the development of kidney stones.  The reported incidence was 1.5% (32 of 2,086 patients) during premarketing use, which is about 2 to 4 times that expected in a similar, untreated population.  Topiramate is a weak carbonic anhydrase inhibitor and may promote stone formation by reducing urinary citrate excretion and increasing urinary pH.  Therapy with topiramate should be administered cautiously with adequate hydration in patients with a history of nephrolithiasis.  The concomitant use of topiramate with other carbonic anhydrase inhibitors should be avoided.  Patients who are dehydrated may be at increased risk for the development of nephrolithiasis and should be encouraged to consume additional amounts of liquid during topiramate therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28800, 27429, 'Topiramate', 'Nephrolithiasis', 'The use of topiramate may infrequently be associated with the development of kidney stones.  The reported incidence was 1.5% (32 of 2,086 patients) during premarketing use, which is about 2 to 4 times that expected in a similar, untreated population.  Topiramate is a weak carbonic anhydrase inhibitor and may promote stone formation by reducing urinary citrate excretion and increasing urinary pH.  Therapy with topiramate should be administered cautiously with adequate hydration in patients with a history of nephrolithiasis.  The concomitant use of topiramate with other carbonic anhydrase inhibitors should be avoided.  Patients who are dehydrated may be at increased risk for the development of nephrolithiasis and should be encouraged to consume additional amounts of liquid during topiramate therapy.', '2', '', 'DDInter', 0);
